| |
|
|
|
|
| Slide Lecture Programs |
| 2006 Core Curriculum |
| Contemporary Management of Myocardial Ischemia |
May 17, 2006
|
| V: |
New Therapeutic Options for Chronic Stable Angina |
Slide 47 |
|
Download PowerPoint
|
INITIATIVE: Study design
- Two clinical trials have assessed the antianginal efficacy of ivabradine. The first was a placebo-controlled evaluation.1 INITIATIVE (International Trial on the Treatment of Angina with Ivabradine vs Atenolol), the second, was a comparison of ivabradine and atenolol.2
- INITIATIVE was designed to evaluate the noninferiority of ivabradine vs atenolol in patients with class I to III angina.
- Placebo washout of prior antianginal medications lasted from 2 to 7 days, depending on the half-life of the medication. Subjects then entered a 7-day qualifying period, after which they were randomized to atenolol 50 mg or ivabradine 5 mg.
- After 4 weeks, atenolol was increased to 100 mg and ivabradine to 7.5 mg or 10 mg and treatment was continued for an additional 12 weeks.
- Borer JS, Fox K, Jaillon P, Lerebours G, for the Ivabradine Investigators Group. Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: A randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107:817-823.
- Sulfi S, Timmis AD. Ivabradine -- the first selective sinus node If channel inhibitor in the treatment of stable angina. Int J Clin Pract. 2006;60:222-228.
|
|
|
Resources
